Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by RalphRalphon Aug 01, 2020 2:17pm
237 Views
Post# 31354063

RE:RE:RE: Very interesting!

RE:RE:RE: Very interesting!

That is an important point.  Since Insiders own that much, it tells you that they won't want to keep diluting.   That incentivizes management to either land  a partnership or a buyout.  

Long-term, the investment thesis is strong -  although I  think ATB-346  still carries some risk.   My concern is that the stock may be dead money for the next 6-12 months.   That's not a huge problem, but it does present opportunity cost - especially with ASH coming.

I think the company orginally planned on uplisting very soon after these recent results.    That would have been a big catalyst.  They probably figured that good data would allow a reverse split & uplist to happen - and give the stock price some leeway in terms of staying above NASDAQ minimums.  However, the recent price movement essentially blocks an uplist,  which removes that catalyst until a partnership occurs.

 That's why the issues with the  press release, Insider selling, & dilution  were so problematic.  The price dropped too low for an uplist to safely occur, creating a much bigger catalyst desert.
 


MUGMODs wrote: For what it’s worth ...

Simplest thing for shareholders is to look at the company presentation (dated June 2020) and look at insider ownership.  This will eventually be updated with little change to insider ownership IMO.

Then, also know Wallace and Legault are majority owners of Antibe Holdings.  The original prospectus may have more information for you.

Most of us are well beyond that as we look to the future and not the past.  We are finally at the negotiation stage ... something we have patiently waited for.


Bullboard Posts